Requisition update
RNS & Investor News
2024
Notice of Results
23 March 2016
Analyst Briefing
OptiBiotix Health Plc (AIM: OPTI), a life sciences business developing compounds to tackle obesity, high cholesterol and diabetes, will announce its preliminary results for the year ended 30 November 2015 on Thursday 14 April 2016.
A briefing for analysts will take place in the Gresham room at the London Capital Club, 15 Abchurch Lane, London EC4N 7BW at 9.30am on Thursday 14 April 2016.
If you would like to register to attend the briefing, or require further information, please contact Walbrook PR on 020 7933 8780 or email [email protected].
For further information, please contact:
| OptiBiotix Health Plc Stephen O'Hara, Chief Executive |
www.optibiotix.com Contact via Walbrook below |
| Cairn Financial Advisers LLP Liam Murray / Avi Robinson |
Tel: 020 7148 7900 |
| Hybridan LLP (Joint Broker) Claire Louise Noyce |
Tel: 020 3764 2341 |
| Peterhouse Corporate Finance Ltd (Joint Broker) Duncan Vasey / Lucy Williams |
Tel: 020 7469 0936 |
| Walbrook PR Ltd Anna Dunphy Mike Wort |
Tel: 020 7933 8780 or [email protected] Mob: 07876 741 001 Mob: 07900 608 002 |
2023
Notice of Results
23 March 2016
Analyst Briefing
OptiBiotix Health Plc (AIM: OPTI), a life sciences business developing compounds to tackle obesity, high cholesterol and diabetes, will announce its preliminary results for the year ended 30 November 2015 on Thursday 14 April 2016.
A briefing for analysts will take place in the Gresham room at the London Capital Club, 15 Abchurch Lane, London EC4N 7BW at 9.30am on Thursday 14 April 2016.
If you would like to register to attend the briefing, or require further information, please contact Walbrook PR on 020 7933 8780 or email [email protected].
For further information, please contact:
| OptiBiotix Health Plc Stephen O'Hara, Chief Executive |
www.optibiotix.com Contact via Walbrook below |
| Cairn Financial Advisers LLP Liam Murray / Avi Robinson |
Tel: 020 7148 7900 |
| Hybridan LLP (Joint Broker) Claire Louise Noyce |
Tel: 020 3764 2341 |
| Peterhouse Corporate Finance Ltd (Joint Broker) Duncan Vasey / Lucy Williams |
Tel: 020 7469 0936 |
| Walbrook PR Ltd Anna Dunphy Mike Wort |
Tel: 020 7933 8780 or [email protected] Mob: 07876 741 001 Mob: 07900 608 002 |
2022
Notice of Results
23 March 2016
Analyst Briefing
OptiBiotix Health Plc (AIM: OPTI), a life sciences business developing compounds to tackle obesity, high cholesterol and diabetes, will announce its preliminary results for the year ended 30 November 2015 on Thursday 14 April 2016.
A briefing for analysts will take place in the Gresham room at the London Capital Club, 15 Abchurch Lane, London EC4N 7BW at 9.30am on Thursday 14 April 2016.
If you would like to register to attend the briefing, or require further information, please contact Walbrook PR on 020 7933 8780 or email [email protected].
For further information, please contact:
| OptiBiotix Health Plc Stephen O'Hara, Chief Executive |
www.optibiotix.com Contact via Walbrook below |
| Cairn Financial Advisers LLP Liam Murray / Avi Robinson |
Tel: 020 7148 7900 |
| Hybridan LLP (Joint Broker) Claire Louise Noyce |
Tel: 020 3764 2341 |
| Peterhouse Corporate Finance Ltd (Joint Broker) Duncan Vasey / Lucy Williams |
Tel: 020 7469 0936 |
| Walbrook PR Ltd Anna Dunphy Mike Wort |
Tel: 020 7933 8780 or [email protected] Mob: 07876 741 001 Mob: 07900 608 002 |
2021
Notice of Results
23 March 2016
Analyst Briefing
OptiBiotix Health Plc (AIM: OPTI), a life sciences business developing compounds to tackle obesity, high cholesterol and diabetes, will announce its preliminary results for the year ended 30 November 2015 on Thursday 14 April 2016.
A briefing for analysts will take place in the Gresham room at the London Capital Club, 15 Abchurch Lane, London EC4N 7BW at 9.30am on Thursday 14 April 2016.
If you would like to register to attend the briefing, or require further information, please contact Walbrook PR on 020 7933 8780 or email [email protected].
For further information, please contact:
| OptiBiotix Health Plc Stephen O'Hara, Chief Executive |
www.optibiotix.com Contact via Walbrook below |
| Cairn Financial Advisers LLP Liam Murray / Avi Robinson |
Tel: 020 7148 7900 |
| Hybridan LLP (Joint Broker) Claire Louise Noyce |
Tel: 020 3764 2341 |
| Peterhouse Corporate Finance Ltd (Joint Broker) Duncan Vasey / Lucy Williams |
Tel: 020 7469 0936 |
| Walbrook PR Ltd Anna Dunphy Mike Wort |
Tel: 020 7933 8780 or [email protected] Mob: 07876 741 001 Mob: 07900 608 002 |
2020
Notice of Results
23 March 2016
Analyst Briefing
OptiBiotix Health Plc (AIM: OPTI), a life sciences business developing compounds to tackle obesity, high cholesterol and diabetes, will announce its preliminary results for the year ended 30 November 2015 on Thursday 14 April 2016.
A briefing for analysts will take place in the Gresham room at the London Capital Club, 15 Abchurch Lane, London EC4N 7BW at 9.30am on Thursday 14 April 2016.
If you would like to register to attend the briefing, or require further information, please contact Walbrook PR on 020 7933 8780 or email [email protected].
For further information, please contact:
| OptiBiotix Health Plc Stephen O'Hara, Chief Executive |
www.optibiotix.com Contact via Walbrook below |
| Cairn Financial Advisers LLP Liam Murray / Avi Robinson |
Tel: 020 7148 7900 |
| Hybridan LLP (Joint Broker) Claire Louise Noyce |
Tel: 020 3764 2341 |
| Peterhouse Corporate Finance Ltd (Joint Broker) Duncan Vasey / Lucy Williams |
Tel: 020 7469 0936 |
| Walbrook PR Ltd Anna Dunphy Mike Wort |
Tel: 020 7933 8780 or [email protected] Mob: 07876 741 001 Mob: 07900 608 002 |
2019
Notice of Results
23 March 2016
Analyst Briefing
OptiBiotix Health Plc (AIM: OPTI), a life sciences business developing compounds to tackle obesity, high cholesterol and diabetes, will announce its preliminary results for the year ended 30 November 2015 on Thursday 14 April 2016.
A briefing for analysts will take place in the Gresham room at the London Capital Club, 15 Abchurch Lane, London EC4N 7BW at 9.30am on Thursday 14 April 2016.
If you would like to register to attend the briefing, or require further information, please contact Walbrook PR on 020 7933 8780 or email [email protected].
For further information, please contact:
| OptiBiotix Health Plc Stephen O'Hara, Chief Executive |
www.optibiotix.com Contact via Walbrook below |
| Cairn Financial Advisers LLP Liam Murray / Avi Robinson |
Tel: 020 7148 7900 |
| Hybridan LLP (Joint Broker) Claire Louise Noyce |
Tel: 020 3764 2341 |
| Peterhouse Corporate Finance Ltd (Joint Broker) Duncan Vasey / Lucy Williams |
Tel: 020 7469 0936 |
| Walbrook PR Ltd Anna Dunphy Mike Wort |
Tel: 020 7933 8780 or [email protected] Mob: 07876 741 001 Mob: 07900 608 002 |
2018
Notice of Results
23 March 2016
Analyst Briefing
OptiBiotix Health Plc (AIM: OPTI), a life sciences business developing compounds to tackle obesity, high cholesterol and diabetes, will announce its preliminary results for the year ended 30 November 2015 on Thursday 14 April 2016.
A briefing for analysts will take place in the Gresham room at the London Capital Club, 15 Abchurch Lane, London EC4N 7BW at 9.30am on Thursday 14 April 2016.
If you would like to register to attend the briefing, or require further information, please contact Walbrook PR on 020 7933 8780 or email [email protected].
For further information, please contact:
| OptiBiotix Health Plc Stephen O'Hara, Chief Executive |
www.optibiotix.com Contact via Walbrook below |
| Cairn Financial Advisers LLP Liam Murray / Avi Robinson |
Tel: 020 7148 7900 |
| Hybridan LLP (Joint Broker) Claire Louise Noyce |
Tel: 020 3764 2341 |
| Peterhouse Corporate Finance Ltd (Joint Broker) Duncan Vasey / Lucy Williams |
Tel: 020 7469 0936 |
| Walbrook PR Ltd Anna Dunphy Mike Wort |
Tel: 020 7933 8780 or [email protected] Mob: 07876 741 001 Mob: 07900 608 002 |
2017
Notice of Results
23 March 2016
Analyst Briefing
OptiBiotix Health Plc (AIM: OPTI), a life sciences business developing compounds to tackle obesity, high cholesterol and diabetes, will announce its preliminary results for the year ended 30 November 2015 on Thursday 14 April 2016.
A briefing for analysts will take place in the Gresham room at the London Capital Club, 15 Abchurch Lane, London EC4N 7BW at 9.30am on Thursday 14 April 2016.
If you would like to register to attend the briefing, or require further information, please contact Walbrook PR on 020 7933 8780 or email [email protected].
For further information, please contact:
| OptiBiotix Health Plc Stephen O'Hara, Chief Executive |
www.optibiotix.com Contact via Walbrook below |
| Cairn Financial Advisers LLP Liam Murray / Avi Robinson |
Tel: 020 7148 7900 |
| Hybridan LLP (Joint Broker) Claire Louise Noyce |
Tel: 020 3764 2341 |
| Peterhouse Corporate Finance Ltd (Joint Broker) Duncan Vasey / Lucy Williams |
Tel: 020 7469 0936 |
| Walbrook PR Ltd Anna Dunphy Mike Wort |
Tel: 020 7933 8780 or [email protected] Mob: 07876 741 001 Mob: 07900 608 002 |
2016
Notice of Results
23 March 2016
Analyst Briefing
OptiBiotix Health Plc (AIM: OPTI), a life sciences business developing compounds to tackle obesity, high cholesterol and diabetes, will announce its preliminary results for the year ended 30 November 2015 on Thursday 14 April 2016.
A briefing for analysts will take place in the Gresham room at the London Capital Club, 15 Abchurch Lane, London EC4N 7BW at 9.30am on Thursday 14 April 2016.
If you would like to register to attend the briefing, or require further information, please contact Walbrook PR on 020 7933 8780 or email [email protected].
For further information, please contact:
| OptiBiotix Health Plc Stephen O'Hara, Chief Executive |
www.optibiotix.com Contact via Walbrook below |
| Cairn Financial Advisers LLP Liam Murray / Avi Robinson |
Tel: 020 7148 7900 |
| Hybridan LLP (Joint Broker) Claire Louise Noyce |
Tel: 020 3764 2341 |
| Peterhouse Corporate Finance Ltd (Joint Broker) Duncan Vasey / Lucy Williams |
Tel: 020 7469 0936 |
| Walbrook PR Ltd Anna Dunphy Mike Wort |
Tel: 020 7933 8780 or [email protected] Mob: 07876 741 001 Mob: 07900 608 002 |
2015
Notice of Results
23 March 2016
Analyst Briefing
OptiBiotix Health Plc (AIM: OPTI), a life sciences business developing compounds to tackle obesity, high cholesterol and diabetes, will announce its preliminary results for the year ended 30 November 2015 on Thursday 14 April 2016.
A briefing for analysts will take place in the Gresham room at the London Capital Club, 15 Abchurch Lane, London EC4N 7BW at 9.30am on Thursday 14 April 2016.
If you would like to register to attend the briefing, or require further information, please contact Walbrook PR on 020 7933 8780 or email [email protected].
For further information, please contact:
| OptiBiotix Health Plc Stephen O'Hara, Chief Executive |
www.optibiotix.com Contact via Walbrook below |
| Cairn Financial Advisers LLP Liam Murray / Avi Robinson |
Tel: 020 7148 7900 |
| Hybridan LLP (Joint Broker) Claire Louise Noyce |
Tel: 020 3764 2341 |
| Peterhouse Corporate Finance Ltd (Joint Broker) Duncan Vasey / Lucy Williams |
Tel: 020 7469 0936 |
| Walbrook PR Ltd Anna Dunphy Mike Wort |
Tel: 020 7933 8780 or [email protected] Mob: 07876 741 001 Mob: 07900 608 002 |
2014
Notice of Results
23 March 2016
Analyst Briefing
OptiBiotix Health Plc (AIM: OPTI), a life sciences business developing compounds to tackle obesity, high cholesterol and diabetes, will announce its preliminary results for the year ended 30 November 2015 on Thursday 14 April 2016.
A briefing for analysts will take place in the Gresham room at the London Capital Club, 15 Abchurch Lane, London EC4N 7BW at 9.30am on Thursday 14 April 2016.
If you would like to register to attend the briefing, or require further information, please contact Walbrook PR on 020 7933 8780 or email [email protected].
For further information, please contact:
| OptiBiotix Health Plc Stephen O'Hara, Chief Executive |
www.optibiotix.com Contact via Walbrook below |
| Cairn Financial Advisers LLP Liam Murray / Avi Robinson |
Tel: 020 7148 7900 |
| Hybridan LLP (Joint Broker) Claire Louise Noyce |
Tel: 020 3764 2341 |
| Peterhouse Corporate Finance Ltd (Joint Broker) Duncan Vasey / Lucy Williams |
Tel: 020 7469 0936 |
| Walbrook PR Ltd Anna Dunphy Mike Wort |
Tel: 020 7933 8780 or [email protected] Mob: 07876 741 001 Mob: 07900 608 002 |
2013
Notice of Results
23 March 2016
Analyst Briefing
OptiBiotix Health Plc (AIM: OPTI), a life sciences business developing compounds to tackle obesity, high cholesterol and diabetes, will announce its preliminary results for the year ended 30 November 2015 on Thursday 14 April 2016.
A briefing for analysts will take place in the Gresham room at the London Capital Club, 15 Abchurch Lane, London EC4N 7BW at 9.30am on Thursday 14 April 2016.
If you would like to register to attend the briefing, or require further information, please contact Walbrook PR on 020 7933 8780 or email [email protected].
For further information, please contact:
| OptiBiotix Health Plc Stephen O'Hara, Chief Executive |
www.optibiotix.com Contact via Walbrook below |
| Cairn Financial Advisers LLP Liam Murray / Avi Robinson |
Tel: 020 7148 7900 |
| Hybridan LLP (Joint Broker) Claire Louise Noyce |
Tel: 020 3764 2341 |
| Peterhouse Corporate Finance Ltd (Joint Broker) Duncan Vasey / Lucy Williams |
Tel: 020 7469 0936 |
| Walbrook PR Ltd Anna Dunphy Mike Wort |
Tel: 020 7933 8780 or [email protected] Mob: 07876 741 001 Mob: 07900 608 002 |
Latest RNS News
Latest Video
ProBiotix Health anticipating "big commercial opportunities" during 2023
Group CEO Stephen O’Hara and CEO Steen Anderson | 04 January 2023
www.proactiveinvestors.co.uk
Latest Podcast
Stephen OHara interview with Investors Champion
Stephen O'Hara | 04 Jul 2019
www.investorschampion.com